Popular weight loss drugs in tight supply as Zepbound shortage could last through June
Weight loss drugs, including Wegovy and Zepbound, are still in tight supply as a shortage of the latter could last through June.
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
Two pharmaceutical companies, Eli Lilly (LLY) and Novo Nordisk (NVO), are leading the weight-loss revolution with a new class of drugs known as GLP-1 agonists. Surging revenue and growing excitement has led some analysts to compare the success of GLP-1 drugs in the health and wellness market to the artificial intelligence boom in the tech industry.
Eli Lilly soars 8% after Q1 earnings reveal surging popularity for its Zepbound weight-loss drug
"Demand continues to outstrip even increased supply," Eli Lilly's CFO said of its Zepbound weight loss drug on the company's conference call.
Poll: 1 in 8 U.S. adults have tried weight-loss drugs like Wegovy, Ozempic
About 1 in 8 U.S. adults (12%) have tried a weight-loss drug like Wegovy, Ozempic, Zepbound or Mounjaro, a new KFF Health Tracking Poll says.
One in eight U.S. adults have taken Ozempic or similar weight loss drugs
One in eight US adults has tried medications from the fast-growing class of new diabetes and obesity drugs that includes Ozempic and Zepbound,
Is it ever OK to ask if someone's on Ozempic? Here's what experts say about questions regarding weight loss drugs.
With the rise in popularity of weight loss drugs such as Ozempic, discussions about weight loss are once again ramping up. But while some people are open about using medication to slim down — or slimming down as a result of using medication to treat a condition such as type 2 diabetes — others consider commenting on or speculating about someone
MedPage Today on MSN20h
Slow Responders to Zepbound Achieve Meaningful Weight Loss Eventually
NEW ORLEANS -- The vast majority of patients with obesity who responded slowly to the once-weekly injectable tirzepatide ...
1 No-Brainer Growth Stock to Buy and Hold
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a ...
Everyday Health on MSN10d
Wegovy and Zepbound Shortages Will Last Until Summer
The FDA anticipates limited availability of most doses of the GLP-1 weight loss drugs Wegovy and Zepbound at least through ...
STAT10d
Eli Lilly raises earnings guidance as it ramps up Mounjaro, Zepbound manufacturing
Eli Lilly raised its full-year guidance while it reported strong first-quarter sales of Zepbound, its obesity drug.
Discover Magazine on MSN8d
The Difference Between Zepbound and Ozempic, and How They Work
The active ingredients in these popular type 2 diabetes treatments are being used to treat a wide range of health conditions.
The Financial Times3d
Eli Lilly lifts guidance after sales of Mounjaro and Zepbound drugs soar
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Soaring sales of Eli Lilly’s hugely popular diabetes and weight loss drugs Mounjaro and Zepbound prompted ...
Eli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
U.S. News & World Report11d
Lilly Rides Mounjaro, Zepbound to Better-Than-Expected 1Q Profit Despite Supply Issues
Lilly Rides Mounjaro, Zepbound to Better-Than-Expected 1Q Profit Despite Supply Issues Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro ...
Lilly could partner with Cipla to market GLP-1 drugs in India - report
Cipla is open to partnering with Eli Lilly to market Mounjaro for diabetes and Zepbound for weight loss in India.